抗糖尿病药物对肌少症影响的研究进展  

Exploring the impact of anti-diabetic medications on sarcopenia:a comprehensivereview

作　　者：谭莅唐 付颖[2,3] Litang Tan;Ying Fu(Beijing Luhe Hospital,Capital Medical University,Beijing 101149,China;Center for Endocrine Metabolism and Immune Diseases,Beijing Luhe Hospital,Capital Medical University,Beijing 101149,China;Beijing Key Laboratory of Diabetes Research and Care,Beijing 101149,China)

机构地区：[1]首都医科大学附属北京潞河医院,北京101149 [2]首都医科大学附属北京潞河医院内分泌代谢与免疫性疾病中心,北京101149 [3]糖尿病防治研究北京市重点实验室,北京101149

出　　处：《Journal of Chinese Pharmaceutical Sciences》2024年第6期481-494,共14页中国药学（英文版）

基　　金：Capital Medical University “Undergraduate Scientific Research Innovation” Project (Grant No. XSKY2021387)。

摘　　要：肌少症是一种肌肉量减少和(或)肌肉功能下降的疾病,极大地增加了老年人跌倒、骨折甚至死亡的风险。糖尿病可并发肌少症,但其病因及机制尚不明确。而且, 2型糖尿病患者使用的抗糖尿病药物,除了抗糖尿病作用外,还可以通过不同的机制作用于骨骼肌,影响蛋白质合成与分解之间的平衡,从而导致肌少症的发生。本文阐述了抗糖尿病药物对肌少症的潜在作用机制,并提供了相关的临床研究和数据。Sarcopenia is a condition characterized by a reduction in muscle mass and/or diminished muscle function,significantly amplifying the risk of falls,fractures,and even mortality among the elderly.Although diabetes can be further complicated by sarcopenia,the precise cause and mechanism remain unclear.Moreover,the impact of anti-diabetic medications,commonly used by individuals with type 2 diabetes,extends beyond glycemic control.These drugs can influence skeletal muscle through diverse mechanisms,affecting the delicate balance between protein synthesis and breakdown,thereby contributing to the development of sarcopenia.This article delves into the potential mechanisms of anti-diabetic drugs on sarcopenia,offering insights from relevant clinical studies and data.

关 键 词：肌少症 抗糖尿病药物 骨骼肌 糖尿病 

分 类 号：R97[医药卫生—药品]